Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 2/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.47 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.46 |
| ▸ | TUBB4A | P04350 | 5/20 | 0.43 |
| ▸ | TUBB | P07437 | 5/20 | 0.43 |
| ▸ | TUBA3C | P0DPH7 | 5/20 | 0.43 |
| ▸ | TUBA1B | P68363 | 5/20 | 0.43 |
| ▸ | TUBA4A | P68366 | 5/20 | 0.43 |
| ▸ | TUBB4B | P68371 | 5/20 | 0.43 |
| ▸ | TUBB3 | Q13509 | 5/20 | 0.43 |
| ▸ | TUBB2A | Q13885 | 5/20 | 0.43 |
| ▸ | TUBB8 | Q3ZCM7 | 5/20 | 0.43 |
| ▸ | TUBA3E | Q6PEY2 | 5/20 | 0.43 |
| ▸ | TUBA1A | Q71U36 | 5/20 | 0.43 |
| ▸ | TUBA1C | Q9BQE3 | 5/20 | 0.43 |
| ▸ | TUBB6 | Q9BUF5 | 5/20 | 0.43 |
| ▸ | TUBB2B | Q9BVA1 | 5/20 | 0.43 |
| ▸ | TUBB1 | Q9H4B7 | 5/20 | 0.43 |
| ▸ | FYN | P06241 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1341491 | 0.87 | NFE2L2 (0.46) | NFE2L2TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL1339084 | 0.86 | AR (0.43) | SLC6A2SLC6A4SLC6A3NFE2L2APP | |
| SCHEMBL1341358 | 0.85 | SLC6A2 (0.50) | SLC6A2SLC6A4SLC6A3NFE2L2MAPT | |
| SCHEMBL1340219 | 0.84 | ALDH1A1 (0.61) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL1341410 | 0.84 | ALDH1A1 (0.40) | NFE2L2TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL1340914 | 0.81 | ALDH1A1 (0.63) | NFE2L2APPMAPTL3MBTL1CYP19A1 | |
| SCHEMBL29937119 | 0.80 | ALDH1A1 (0.59) | SLC6A2SLC6A4SLC6A3NFE2L2TUBB4A | |
| SCHEMBL112310 | 0.80 | ALDH1A1 (0.59) | SLC6A2SLC6A4SLC6A3NFE2L2TUBB4A | |
| SCHEMBL22069591 | 0.79 | CYP19A1 (0.44) | NFE2L2FYNMAPTCYP19A1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL27462411 | 0.79 | ALDH1A1 (0.61) | SLC6A2SLC6A4SLC6A3NFE2L2TUBB4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE45670-E1 | Aryl carbonyl derivatives as therapeutic agents | NOVO NORDISK A/S (DK) | 2015-09-15 | — | — | US | disclosed |
| EP-2471533-A1 | Aryl carbonyl derivatives as therapeutic agents | Novo Nordisk A/S (DK) | 2012-07-04 | — | — | EP | disclosed |
| US-20110301158-A1 | ARYL CARBONYL DERIVATIVES AS THERAPEUTIC AGENTS | NOVO NORDISK A/S (DK) | 2011-12-08 | — | — | US | disclosed |
| US-8063081-B2 | N-(2-Phenoxyphenyl)-N'-(thiazol-2-yl)urea; glucokinase inhibitor; antidiabetic, hypoglycemic agent; activators of glucokinase | NOVO NORDISK A/S (DK) | 2011-11-22 | — | — | US | disclosed |
| US-7897628-B2 | {2-[3-(4-Methyl-2-[2-methypropoxy]phenyl)-ureido]-thiazol-4-yl}-acetic acid ethyl ester; glucokinase inhibitor; antidiabetic, hypoglycemic agent; activators of glucokinase | NOVO NORDISK A/S (DK) | 2011-03-01 | — | — | US | disclosed |
| US-7541373-B2 | Aryl carbonyl derivatives as therapeutic agents | NOVO NORDISK A/S (DK) | 2009-06-02 | — | — | US | disclosed |
| US-7384967-B2 | Aryl carbonyl derivatives as therapeutic agents | NOVO NORDISK A/S (DK) | 2008-06-10 | — | — | US | disclosed |
| US-20080119454-A1 | Aryl carbonyl derivatives as therapeutic agents | NOVO NORDISK A/S (DK) | 2008-05-22 | — | — | US | disclosed |
| US-20080119455-A1 | Aryl carbonyl derivatives as therapeutic agents | NOVO NORDISK A/S (DK) | 2008-05-22 | — | — | US | disclosed |
| US-20060183783-A1 | Aryl carbonyl derivatives as therapeutic agents | VTV THERAPEUTICS LLC | 2006-08-17 | — | — | US | disclosed |
| EP-1531815-A1 | GLUCOKINASE ACTIVATORS | NOVO NORDISK A/S (DK) | 2005-05-25 | — | — | EP | disclosed |
| US-20040122235-A1 | Aryl carbonyl derivatives as therapeutic agents | VTV THERAPEUTICS LLC | 2004-06-24 | — | — | US | disclosed |
| WO-2004002481-A1 | ARYL CARBONYL DERIVATIVES AS THERAPEUTIC AGENTS | NOVO NORDISK A/S (DK) | 2004-01-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110301158-A1 | ARYL CARBONYL DERIVATIVES AS THERAPEUTIC AGENTS | GCK, GCKR, PDK2 | SLC6A2 4227/4885SLC6A4 3948/4885SLC6A3 3287/4885 |
| US-20080119455-A1 | Aryl carbonyl derivatives as therapeutic agents | GCK, GCKR, PDK2 | SLC6A2 4227/4885SLC6A4 3948/4885SLC6A3 3287/4885 |
| US-20060183783-A1 | Aryl carbonyl derivatives as therapeutic agents | GCK, PDK3, PDK4 | SLC6A2 4358/4885SLC6A4 4054/4885SLC6A3 2967/4885 |
| US-20040122235-A1 | Aryl carbonyl derivatives as therapeutic agents | GCK, GCKR, PDK2 | SLC6A2 4227/4885SLC6A4 3948/4885SLC6A3 3287/4885 |
| US-20080119454-A1 | Aryl carbonyl derivatives as therapeutic agents | GCK, GCKR, PDK2 | SLC6A2 4227/4885SLC6A4 3948/4885SLC6A3 3287/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.